Research use onlyNot for human or veterinary use
ENCORE BIO LABSRESEARCH COLLECTION
Semax + Selank — complete Encore Bio Labs reference vialMATERIAL / 20

Reference artwork · Legacy packaging may be shown.
Listed identity and formats take precedence over the image.

Research material

Semax + Selank

Discover two distinct angles on experimental neuroscience. Semax research examines gene and protein responses in animal models; Selank studies in rats focus on gene activity linked to GABA signaling. This pairing brings both names together, with the science of each component offering its own questions to explore.

Components
80714-61-0 / 129954-34-3

Formats & reference pricing

USD
Listed formatReference price
10 mg + 10 mg$89 USD

Reference prices describe the listed formats. They do not confirm availability or constitute an offer for sale.

Review product documentation

For laboratory research only. Not for human or veterinary use.

Two sequences sharing one listing

This listing names two separate heptapeptides. Semax is indexed as Met-Glu-His-Phe-Pro-Gly-Pro and Selank as Thr-Lys-Pro-Arg-Pro-Gly-Pro. Both end with proline-glycine-proline, yet their first four residues differ entirely. A combined listing is two molecular references, not a single new sequence, and the quantity of each requires its own records.

Reference sequences
MEHFPGP and TKPRPGP
Listing detail
Two heptapeptides; listed as equal parts, records pending

Reference identity only; not a test result for current inventory.

01 / Material overview

The specifications.

Catalog identity
Semax + Selank
Components
80714-61-0 / 129954-34-3
Listed formats
10 mg + 10 mg
Reference price range
$89 USD
Intended setting
Qualified laboratory or institutional research
Inventory specifications
Independent inventory review pending

02 / Regulatory context

Regulatory & safety notes.

FDA’s public compounding materials can provide regulatory safety context. They do not verify a current Encore Bio Labs lot.

FDA PUBLIC RECORD · REVIEWED OCT 2026Semax + Selank

FDA compounding record · Semax + Selank

FDA lists Semax and selank acetate separately among withdrawn bulk-substance nominations and describes potential immunogenicity concerns related to aggregation and peptide-related impurities for each, with limited or lacking safety information. The combination itself is not represented here as FDA-evaluated or approved.

Separate component-level FDA records do not verify the composition, proportion, purity, sterility, potency, or suitability of this combined listing.

FDA record type
Human drug compounding safety context
Human-use guidance
Not provided

03 / Supporting records

Documentation.

Read the Encore summary, the scope of related reports and the status of privacy-redacted supplier copies.

No authenticated certificate establishing current-inventory identity or specifications is published for Semax + Selank in this catalog.

Encore documentary summary · not a laboratory-issued COA

Report availability
Not located in the reviewed set
Formats & scope
No related report was located in the reviewed set. This does not establish that no document exists elsewhere.
Report authenticity
No report to authenticate
Inventory evidence review
Report-to-inventory correspondence has not been independently established. No purity, quantity or activity result is attributed to current inventory.
Outstanding review
Obtain supporting records that confirm 10 mg of each peptide in the listed 10 mg + 10 mg format. Separate Semax or Selank reports do not establish the combination.
Product-specific SDS
Not located in the reviewed PDF set; applicability and verification pending.

Document inventory reviewed October 6, 2026. Related reports were commissioned by third parties, not Encore. Original customer details and internal records are not included here.

Privacy-redacted supplier report

Report not on file

Where prepared, these are copies redacted by Encore for privacy, not laboratory-issued public versions or Encore-commissioned tests. Analytical content is not replaced with Encore results.

Copy preparation
0 source files in redacted review copies. Duplicate file formats are not additional tests.
Supplier sharing permission
Owner-confirmed for supplied reports; this does not imply a report exists for every product. Report authentication is a separate check.
Privacy review
No source to review. Retained references and copies elsewhere can still identify the original customer; redaction does not guarantee anonymity.
Downloads
No website copy released. No download is available for this product.
Laboratory-issued public copy
Not available. Encore-prepared redactions are not an issuer reissue.

First locate the source report for the material and format; then review privacy, scope and verification.

A public copy does not by itself verify current inventory. No laboratory replacement or delivery date is promised.

Explore summary & report status

04 / A closer look

Common questions.

01Which Semax + Selank formats and reference prices are listed?

10 mg + 10 mg: $89 USD. These are catalog quantities and reference prices, not usage instructions, stock confirmation or an offer for sale.

02Where can I find the Semax + Selank reports?

Report not on file. The Documentation section on this page lists the reviewed source status and outstanding items for this material. No public PDF is available for this product; an unreleased or missing document is not a certificate of current inventory.

03Does the image establish the contents of a lot?

No. The image is owned Encore Bio Labs reference artwork and may show legacy packaging. Use the written identity and specifications, then verify the exact lot with supporting records.

04How should research suitability be assessed?

Qualified personnel should evaluate material identity, lot-specific records, institutional requirements, and study design. Report not on file. Independent inventory review remains pending, and no product-specific SDS was located in the reviewed set. This catalog provides no personal-use or preparation guidance.